Chon, H. J., Kim, S. T., Rha, S. Y., Ryoo, B., El-Khoueiry, A. B., Oh, D., Grewal, J. S., Kim, J., Ahn, H. (., Ryu, S., Choi, J., Nam, K. (2025). A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2606